Methods for treating inflammatory disorders using regulators of microvessel dilations
The invention relates to methods for treating inflammatory diseases. Methods for analyzing microcirculation structural changes are also provided.
1 . A method for treating a subject having a disease involving inflammation, comprising:
administering an inhibitor of angiogenesis in an amount sufficient to inhibit the formation of acute microvessel dilations.
2 . The method of claim 1 , wherein the subject has an autoimmune disease.
3 . The method of claim 2 , wherein the autoimmune disease is an autoimmune disease of the lung.
4 . The method of claim 3 , wherein the subject has idiopathic pulmonary fibrosis.
5 . The method of claim 3 , wherein the subject has interstitial lung disease.
6 . The method of claim 3 , wherein the subject has or is at risk of transplant rejection.
7 . The method of claim 2 , wherein the autoimmune disease is Crohn's disease.
8 . The method of claim 2 wherein the subject has ulcerative colitis.
9 . The method of claim 1 , further comprising administering an inhibitor of lymphocyte cell-cell adhesion.
10 . The method of claim 9 wherein the inhibitor of lymphocyte cell-cell adhesion is selected from the group consisting of an inhibitor of one of LFA-1, CAM 1, and L-selectin.
11 . A method for treating a subject having an inflammatory bowel disease, comprising:
administering an inhibitor of angiogenesis in an amount sufficient to treat the inflammatory bowel disease.
12 . The method of claim 11 , further comprising administering an inhibitor of lymphocyte cell-cell adhesion.
13 . The method of claim 12 , wherein the inhibitor of lymphocyte cell-cell adhesion is selected from the group consisting of an inhibitor of one of LFA-1, CAM 1, and L-selectin.
14 . The method of claim 11 , wherein the inflammatory bowel disease is Crohn's disease.
15 . The method of claim 11 , wherein the inflammatory bowel disease is ulcerative colitis.
16 . A method for analyzing microcirculation structural changes, comprising:
labeling systemic microcirculation with a lipophilic carbocyanine tracer and
performing fluorescence microscopy to analyze the microcirculation structural changes.
17 . The method of claim 16 , where in the structural changes are acute.
18 . The method of claim 16 , wherein the structural changes are chronic.
19 . The method of claim 16 , wherein the method is combined with a method of scanning electron microscopy.
20 . A method for treating a subject having a disease involving inflammation, comprising:
administering an inhibitor of dilatation in an amount sufficient to inhibit the formation of acute microvessel dilations.
21 . The method of claim 20 , wherein the inhibitor of dilatation is an inhibitor of angiogenesis.
22 . The method of claim 20 , wherein the subject has an autoimmune disease.
23 . The method of claim 22 , wherein the autoimmune disease is an autoimmune disease of the lung.
24 . The method of claim 23 , wherein the subject has idiopathic pulmonary fibrosis.
25 . The method of claim 23 , wherein the subject has interstitial lung disease.
26 . The method of claim 23 , wherein the subject has or is at risk of transplant rejection.
27 . The method of claim 22 , wherein the autoimmune disease is Crohn's disease.
28 . The method of claim 22 wherein the subject has ulcerative colitis.
29 . The method of claim 20 , further comprising administering an inhibitor of lymphocyte cell-cell adhesion.
30 . The method of claim 29 wherein the inhibitor of lymphocyte cell-cell adhesion is selected from the group consisting of an inhibitor of one of LFA-1, CAM 1, and L-selectin.
31 . The method of claim 20 , wherein the inhibitor of dilatation is an inhibitor of BMPs.